Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs.
Company facts
| Company | Merck & Co., Inc. |
|---|---|
| Symbol | MRK |
| Exchange | XNYS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $357.02B (Massive market data, 2026-09-10) |
| Employees | 75,000 |
| Country | United States |
| Website | https://www.merck.com |
Trading — Merck & Co., Inc.
| Last price | $143.90 |
|---|---|
| Change | -0.56% |
| Previous close | $144.71 |
| Day range | $143.68 – $145.90 |
| 50-day average | $135.35 |
| 200-day average | $118.93 |
| Average volume | 11,620,245 |
Price basis: 2026-09-11T20:59:30.543758+00:00
Valuation and financial health
| Earnings per share | $1.29 |
|---|---|
| Price / book | 8.51 |
| Price / cash flow | 17.88 |
| Enterprise value / EBITDA | 29.49 |
| Enterprise value / sales | 6.07 |
| Debt / equity | 1.29 |
| Current ratio | 1.32 |
| Dividend yield | 2.32% |
| Free cash flow | $16.06B |
| Cash ratio | 0.25 |
| Enterprise value | $404.08B |
Reported 2026-09-10
Earnings
| Report date | 2026-10-29 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $2.27 |
| Year-ago EPS | $2.58 |
| Analyst estimates | 5 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for MRK are on the IntelTrends dashboard.